1. Scrip
  2. >>Business
  3. >>Earnings

Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market

 
• By Alaric DeArment

Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.

Lilly announced its first quarter 2023 earnings • Source: Shutterstock

Eli Lilly and Company’s Mounjaro (tirzepatide) stole the show in the Indianapolis-based drug maker’s first quarter earnings, showing stronger than expected sales as well as positive results in a Phase III trial that should clinch a US Food and Drug Administration approval of the drug as a weight-loss medication in adults with type 2 diabetes.

The firm reported first quarter revenues of $6.96bn, an 11% decrease from the first quarter of 2022 that the company attributed to lower realized prices, lower volume and an unfavorable effect of foreign exchange rates, with the lower volume in particular stemming from a $1.47bn loss of revenue from antibodies to treat COVID-19

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s Most Favored Nation Policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company, as she and MD Nilesh Gupta outline a five-year plan focused on complex generics and technology platforms

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.